Despite a mixed fourth-quarter revenue performance, British pharmaceutical giant GSK remains optimistic about its long-term growth prospects, particularly with its ambitious revenue target for 2031.

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, and 6.9 per cent, respectively, driving overall IPM growth ...